XJPX
4671
Market cap167mUSD
Oct 09, Last price
2,670.00JPY
1D
0.75%
1Q
-0.45%
Jan 2017
81.51%
Name
Falco Holdings Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
FALCO HOLDINGS Co., Ltd., a medical services enterprise established in 1962 and headquartered in Kyoto, Japan, primarily delivers clinical diagnostic testing and pharmaceutical dispensing solutions. The company serves medical institutions and various corporations throughout Japan. Its comprehensive range of clinical testing encompasses specialized areas such as genetics, biochemistry, hematology, pathology, immunology, microbiology, and radioimmunoassay. Beyond direct diagnostics, FALCO HOLDINGS also engages in genomic-based drug discovery and the development of biotechnological pharmaceuticals. The company's offerings extend to medical information technology services, as well as environmental and food sanitation testing. They also provide genetic testing tailored for the food industry, catering to manufacturers, retailers, and restaurants. Additionally, FALCO HOLDINGS operates dispensing pharmacies and drugstores. They are also active in the development and sale of medical information systems, notably including "@home Dr.," an electronic medical record system designed for clinics with a high volume of clinical testing, and "TASCAL for ASP," a robust medical support system.
Key people
Yoichi Kawata
Managing Executive Officer, Manager of Clinical Business Office, President of Subsidiary, Director · since 2023
Osamu Abe
Executive Officer, Manager of Pharmaceutical Business Office · since 2023
Hisayuki Ohma
Executive Officer, Assistant Manager of Pharmaceutical Business · since 2024
Kayoko Sato
Executive Officer, Assistant Manager of Pharmaceutical Business Office · since 2025
Kei Shimada
Executive Officer, Manager of ICT Business Office, Assistant Manager of Genome Business Officer, Director · since 2025
Takafumi Fukui
Senior Managing Executive Officer, Manager of Genome Business, Director · since 2024
Tetsuo Goda
Manager of Business Planning Office, Director · since 2024
Masahiro Ida
Director · since 2023
Shuhei Kuroda
Executive Officer, Manager of Administration Office, Assistant Manager of ICT Business Office, Director · since 2025
Tadashi Yasuda
President, Executive president, Representative Director · since 2024
Mitsuo Isoda
Independent Director · since 2025
Takehiro Katsuyama
Independent Director · since 2018
Independent Director · since 2021
Masaharu Takai
Independent Director · since 2024
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||